ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Alphamab Oncology and CSPC Pharmaceutical Group side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Alphamab OncologyCSPC Pharmaceutical Group
studies on the registry40357
open to participants now16172
phase 3 studies under way565
reach primary completion within a year755
programswith a study of their own in two years868+3 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAlphamab OncologyCSPC Pharmaceutical Group
Phase 1

Alphamab Oncology: 5 of its 8 programs at phase 1

  1. aflutinibphase 1
  2. JSKN016HCphase 1
  3. JSKN021phase 1
  4. JSKN022phase 1
  5. JSKN027phase 1
63%

CSPC Pharmaceutical Group: 16 of its 68 programs at phase 1

  1. JMT206phase 1
  2. SYH2082phase 1
  3. JMT106phase 1
  4. paclitaxel cationic liposome for injectionphase 1
  5. palbociclibphase 1

and 11 more — sign in to see them all

24%
Phase 200%

CSPC Pharmaceutical Group: 26 of its 68 programs at phase 2

  1. Anti-PD-1/IL-15 Fusion Protein JMT108phase 2
  2. SYS6006 COVID-19 vaccinephase 2
  3. ATM Inhibitor SYH2051phase 2
  4. SYH2069phase 2
  5. SYH2070phase 2

and 21 more — sign in to see them all

38%
Phase 3

Alphamab Oncology: 3 of its 8 programs at phase 3

  1. JSKN016phase 3
  2. JSKN033phase 3
  3. anbenitamab repodatecanphase 3
38%

CSPC Pharmaceutical Group: 25 of its 68 programs at phase 3

  1. Anti-EGFR Antibody-drug Conjugate CPO301phase 3
  2. Docetaxelphase 3
  3. enlonstobartphase 3
  4. becotatugphase 3
  5. anbenitamabphase 3

and 20 more — sign in to see them all

37%
Approved, new studies00%

CSPC Pharmaceutical Group: 1 of its 68 programs at approved, new studies

  1. Tenecteplaseapproved, new study
1%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Alphamab Oncology4 readouts · 1 phase 3·

Alphamab Oncology, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. anbenitamab repodatecanphase 3 · Dec 30 · NCT06751485
  2. JSKN033phase 3 · Dec 31 · NCT06770881
·····

Alphamab Oncology, Jun ’27: 1 program whose next study reaches primary completion

  1. JSKN016phase 3 · Jun 30 · NCT06942234
·

Alphamab Oncology, Aug ’27: 1 program whose next study reaches primary completion

  1. JSKN022phase 1 · Aug 31 · NCT07292402
··
CSPC Pharmaceutical Group39 readouts · 6 phase 3

CSPC Pharmaceutical Group, Nov ’26: 3 programs whose next study reaches primary completion

  1. SYH2061phase 1 · Nov 24 · NCT07241910
  2. Anti-EGFR Antibody-drug Conjugate CPO301phase 3 · Nov 30 · NCT07256509
  3. Anti-PD-1/IL-15 Fusion Protein JMT108phase 2 · Nov 30 · NCT07280832

CSPC Pharmaceutical Group, Dec ’26: 6 programs whose next study reaches primary completion, 2 in phase 3

  1. anbenitamabphase 3 · Dec 16 · NCT06747338
  2. Docetaxelphase 3 · Dec 16 · NCT06747338
  3. glumetinibphase 3 · Dec 25 · NCT06525350
  4. paliperidoneno phase · Dec 31 · NCT07493551
  5. SYH2059phase 2 · Dec 31 · NCT07510958

and 1 more — sign in to see them all

CSPC Pharmaceutical Group, Jan ’27: 4 programs whose next study reaches primary completion

  1. SYH2056phase 1 · Jan 30 · NCT07771777
  2. SYH2082phase 1 · Jan 30 · NCT07532655
  3. SYS6005phase 1 · Jan 30 · NCT06958679
  4. SYH2062phase 2 · Jan 31 · NCT07940075

CSPC Pharmaceutical Group, Feb ’27: 4 programs whose next study reaches primary completion

  1. SYH2072phase 2 · Feb 1 · NCT07647783
  2. SYH2092phase 1 · Feb 9 · NCT07776041
  3. JMT206phase 1 · Feb 28 · NCT07840729
  4. SYS6040phase 1 · Feb 28 · NCT06970795

CSPC Pharmaceutical Group, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. A zoster mRNA vaccine SYS6017phase 2 · Mar 10 · NCT07354659
  2. becotatugphase 3 · Mar 26 · NCT06380348
  3. SYS6041phase 2 · Mar 28 · NCT07744763

CSPC Pharmaceutical Group, Apr ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. enlonstobartphase 3 · Apr 0 · NCT06136988
  2. CPO-107phase 2 · Apr 1 · NCT07029139
  3. SYHX1901phase 3 · Apr 28 · NCT06943950
  4. SYH2070phase 2 · Apr 30 · NCT07695597
  5. SYH2085phase 2 · Apr 30 · NCT07798193

CSPC Pharmaceutical Group, May ’27: 1 program whose next study reaches primary completion

  1. anbenitamab repodatecanphase 3 · May 29 · NCT07545044

CSPC Pharmaceutical Group, Jun ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. ATM Inhibitor SYH2051phase 2 · Jun 15 · NCT06775236
  2. bempedoic acidphase 3 · Jun 30 · NCT07623915

CSPC Pharmaceutical Group, Jul ’27: 4 programs whose next study reaches primary completion

  1. ocankitugphase 3 · Jul 1 · NCT07418736
  2. SYH2053phase 3 · Jul 15 · NCT07938034
  3. SYS6045phase 2 · Jul 30 · NCT07122063
  4. CHO cellphase 2 · Jul 31 · NCT07892989

CSPC Pharmaceutical Group, Aug ’27: 2 programs whose next study reaches primary completion

  1. SYHX2008phase 3 · Aug 1 · NCT06505395
  2. JMT203phase 2 · Aug 14 · NCT06868849

CSPC Pharmaceutical Group, Sep ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Aripiprazoleno phase · Sep 5 · NCT07547384
  2. SYH2069phase 2 · Sep 28 · NCT07796477
  3. Tenecteplaseapproved, new study · Sep 30 · NCT07201688

CSPC Pharmaceutical Group, Oct ’27: 2 programs whose next study reaches primary completion

  1. palbociclibphase 1 · Oct 0 · NCT06941142
  2. Sirolimusphase 3 · Oct 0 · NCT06941142
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Alphamab Oncology

New programs 0

None

Reached a new phase 1

  • JSKN033phase 3 · Aug 25 · Uterine Cervical Neoplasms

Study stopped 0

None

Primary completion later 0

None

CSPC Pharmaceutical Group

New programs 6

  • SYH9061phase 2 · first study · Nov 2 · Idiopathic Pulmonary Fibrosis
  • SYS6062phase 2 · first study · Oct 20 · Stomach Neoplasms
  • CHO cellphase 2 · first study · Oct 19 · COVID-19
  • SYH2066phase 2 · first study · Oct 11 · Respiratory Syncytial Virus Infections
  • Generic Drugphase 3 · first study · Sep 28 · Triple Negative Breast Neoplasms
  • SYS6088phase 2 · first study · Sep 20 · Neoplasms

Reached a new phase 3

  • SYH2072phase 2 · Oct 28 · Hyperaldosteronism
  • SYH2069phase 2 · Aug 25 · Obesity
  • SYH2085phase 2 · Aug 25 · Influenza, Human

Study stopped 0

None

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 8 in all. A program counts in each condition its studies name most.

ConditionAlphamab OncologyCSPC Pharmaceutical Group
Breast Neoplasmsboth · compare here

Alphamab Oncology in Breast Neoplasms: 3 programs

  1. JSKN016phase 3
  2. anbenitamab repodatecanphase 3
  3. aflutinibphase 1

Their studies: Alphamab Oncology’s studies of Breast Neoplasms in search

CSPC Pharmaceutical Group in Breast Neoplasms: 10 programs

  1. Anti-EGFR Antibody-drug Conjugate CPO301phase 3
  2. Docetaxelphase 3
  3. anbenitamabphase 3
  4. Sirolimusphase 3
  5. anbenitamab repodatecanphase 3

and 5 more — sign in to see them all

Their studies: CSPC Pharmaceutical Group’s studies of Breast Neoplasms in search

Carcinoma, Non-Small-Cell Lungboth · compare here

Alphamab Oncology in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. JSKN016phase 3
  2. JSKN033phase 3
  3. aflutinibphase 1

Their studies: Alphamab Oncology’s studies of Carcinoma, Non-Small-Cell Lung in search

CSPC Pharmaceutical Group in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. Anti-EGFR Antibody-drug Conjugate CPO301phase 3
  2. Docetaxelphase 3
  3. enlonstobartphase 3
  4. becotatugphase 3
  5. glumetinibphase 3

and 5 more — sign in to see them all

Their studies: CSPC Pharmaceutical Group’s studies of Carcinoma, Non-Small-Cell Lung in search

Stomach Neoplasmsboth · compare here

Alphamab Oncology in Stomach Neoplasms: 1 program

  1. anbenitamab repodatecanphase 3

Their studies: Alphamab Oncology’s studies of Stomach Neoplasms in search

CSPC Pharmaceutical Group in Stomach Neoplasms: 7 programs

  1. Docetaxelphase 3
  2. enlonstobartphase 3
  3. anbenitamabphase 3
  4. anbenitamab repodatecanphase 3
  5. trastuzumab envedotinphase 3

and 2 more — sign in to see them all

Their studies: CSPC Pharmaceutical Group’s studies of Stomach Neoplasms in search

Colorectal Neoplasmsboth · compare here

Alphamab Oncology in Colorectal Neoplasms: 1 program

  1. anbenitamab repodatecanphase 3

Their studies: Alphamab Oncology’s studies of Colorectal Neoplasms in search

CSPC Pharmaceutical Group in Colorectal Neoplasms: 4 programs

  1. becotatugphase 3
  2. anbenitamab repodatecanphase 3
  3. Anti-PD-1/IL-15 Fusion Protein JMT108phase 2
  4. sintilimabphase 2

Their studies: CSPC Pharmaceutical Group’s studies of Colorectal Neoplasms in search

Ovarian Neoplasmsboth · compare here

Alphamab Oncology in Ovarian Neoplasms: 1 program

  1. anbenitamab repodatecanphase 3

Their studies: Alphamab Oncology’s studies of Ovarian Neoplasms in search

CSPC Pharmaceutical Group in Ovarian Neoplasms: 4 programs

  1. enlonstobartphase 3
  2. anbenitamab repodatecanphase 3
  3. trastuzumab envedotinphase 3
  4. SYS6041phase 2

Their studies: CSPC Pharmaceutical Group’s studies of Ovarian Neoplasms in search

Triple Negative Breast Neoplasmsboth · compare here

Alphamab Oncology in Triple Negative Breast Neoplasms: 1 program

  1. JSKN016phase 3

Their studies: Alphamab Oncology’s studies of Triple Negative Breast Neoplasms in search

CSPC Pharmaceutical Group in Triple Negative Breast Neoplasms: 2 programs

  1. Albumin-Bound Paclitaxelphase 3
  2. Generic Drugphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Triple Negative Breast Neoplasms in search

Uterine Cervical Neoplasmsboth · compare here

Alphamab Oncology in Uterine Cervical Neoplasms: 1 program

  1. JSKN033phase 3

Their studies: Alphamab Oncology’s studies of Uterine Cervical Neoplasms in search

CSPC Pharmaceutical Group in Uterine Cervical Neoplasms: 2 programs

  1. enlonstobartphase 3
  2. Sutantatug Envedotinphase 3

Their studies: CSPC Pharmaceutical Group’s studies of Uterine Cervical Neoplasms in search

Neoplasm Metastasisboth · compare here

Alphamab Oncology in Neoplasm Metastasis: 1 program

  1. aflutinibphase 1

Their studies: Alphamab Oncology’s studies of Neoplasm Metastasis in search

CSPC Pharmaceutical Group in Neoplasm Metastasis: 1 program

  1. paclitaxel cationic liposome for injectionphase 1

Their studies: CSPC Pharmaceutical Group’s studies of Neoplasm Metastasis in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Alphamab Oncology 4 of 8 · CSPC Pharmaceutical Group 25 of 68 programs (18 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (CSPC Pharmaceutical Group: 3).